WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Genetic Engineering and Biotechnology News | January 28, 2020
MIT spin-out company Kytopen signed a deal with Cambridge Consultants to co-develop the FlowfectTM system, a scalable process that reportedly yields billions of engineered cells in minutes. The product will streamline the engineering of a wide array of human and human-derived cells for use in next-generation cell therapies, with the goal of expanding access to new medicines, says Paulo Garcia, CEO and co-founder of Kytopen....
Cell and Gene Therapy
Kite, Shoreline Biosciences | June 18, 2021
Kite, a Gilead Company, and Shoreline Biosciences, Inc., a biotechnology firm developing intelligently designed allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and Macrophage cellular immunotherapies achieved from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, announced a strategic partnership today to develop novel cell therapies across a variety of indications.
The collaboration will combine Shoreline’s profound experi...
Research And Markets | June 30, 2020
The "Global Protective Clothing Market for Life Sciences Industry 2019-2028" report has been added to ResearchAndMarkets.com's offering.The publisher predicts that the global market for protective clothing for life sciences industry would witness a CAGR of 6.26% over the forecast period 2019-2028.The growth of this market is primarily being driven by the growing demand for protective clothing from end-users. Additionally, the large investments in research & developm...
PR Newswire | May 15, 2020
While the COVID-19 pandemic continues to evolve, many Cancer Research Institutions and Pharma/Biotech companies are considering how to restart the biomedical research and drug development programs. This may include thinking through meeting the timeline, risk of mitigation actions, and possible program reprioritizations as components of the strategy to return to normal operations. Our preclinical services allow scientists to discover new innovative therapies effective in serious diseases without ...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE